May 31, 2023
BURLINGTON, Mass. , May 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]
May 10, 2023
Announced launch and commercial availability of FUROSCIX® on February 20 th Generated net FUROSCIX revenue of $2.1 million Ended Q1 2023 with cash, cash equivalents and short-term investments o f $116.1 million Company to host investor conference call and webcast today, Wednesday, May 10 , at[…]
May 02, 2023
Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass. , May 02, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care,[…]
Mar 22, 2023
Announced launch and commercial availability of FUROSCIX ® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure Ended Q4 with cash, cash equivalents, restricted cash and investments o f $118.4M[…]
Mar 15, 2023
Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass. , March 15, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient[…]
Feb 23, 2023
BURLINGTON, Mass. , Feb. 23, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]
Feb 21, 2023
BURLINGTON, Mass. , Feb. 21, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced the launch and[…]
Feb 06, 2023
BURLINGTON, Mass. , Feb. 06, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare[…]
Jan 31, 2023
BURLINGTON, Mass. , Jan. 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]
Jan 30, 2023
Commercial launch planned for February 20, 2023 BURLINGTON, Mass. , Jan. 30, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce[…]
